Diversity-centered training to develop cancer drugs for all Americans
Official title: Research Education
Funded at University of California Riverside · NIH-11411337 · Data updated 2026-11-12
A cancer drug research education program aims to build diverse scientists and strengthen how new therapies are developed for diverse patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $222,570 |
| NIH project number | 5U54CA285114-04 |
| Project ID | NIH-11411337 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are aspiring cancer researchers and students from underrepresented communities who want to contribute to inclusive drug development.
✕Less likely to help
Patients may not directly benefit during the training period, but long-term impact could improve drug relevance for diverse populations.
What this research studies
This grant supports a partnership between UC Riverside and City of Hope to create training and curriculum aimed at diversifying cancer drug development. It focuses on building research infrastructure and educational programs so more researchers from underrepresented groups can contribute to basic, translational, and clinical cancer science. Participants would engage in experiences that connect laboratory work, curriculum, and outreach to reflect the ethnic diversity of Inland Southern California. The core aims to prepare the next generation of therapeutics researchers who understand and address the needs of underrepresented patient populations.
Why it matters
Potential benefit: If successful, more diverse researchers could lead to cancer therapies that are effective for a broader patient population.
How similar studies have gone: Prior efforts show that diverse research teams can improve relevance and acceptance of cancer therapies, though this specific collaboration is unique in its cross-institution education core.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Pellecchia, Maurizio — University of California Riverside
- Study coordinator: Pellecchia, Maurizio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.